View Latest Medical and Pharma Bids and Tenders

Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V For The Active Ingredient Guselkumab

Conclusion Of A Non-Exclusive Supplementary Agreement Pursuant To Section 135A Sgb V To Improve Quality And Transparency Within The Framework Of A So-Called "Open House Model"

Conclusion Of Non-Exclusive Discount Agreements According To Section 130 A Paragraph 8 Sgb V In The Period From 01.01.2025 - 30.06.2026

Conclusion Of Non-Exclusive Discount Agreements According To Section 130 A Paragraph 8 Sgb V In The Period From 01.01.2025 To 31.12.2026

Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Sevelamer Hydrochloride (Atc Code According To Who: V03Ae02)

Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) By Means Of An Open-House Model For The Active Ingredient Dimethyl Fumarate (Official Atc Code: L04Ax07)

Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Sevelamer Hydrochloride (Atc Code According To Who: V03Ae02)

Dynamic Purchasing System: Healthcare And General Supplies Dps

Conclusion Of Non-Exclusive Discount Agreements According To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Doxylamine 6.96 Mg / Pyridoxine 8.23 ​​Mg Hvw (Cariban)

Long-Acting Reversible Contraception (Larc) Service 2025